FDA Rejects Merck's Cordaptive

Given the cholesterol-lowering drug's modest test results and unknown long-term effects, rejection by regulators may not be that surprising

The Food & Drug Administration on Apr. 28 rejected one of Merck's (MRK) biggest hopes for a new blockbuster drug, a cholesterol-lowering medicine call Cordaptive. Analysts who had been predicting that the drug could easily top $1 billion in sales were surprised by the news that the agency sent a "Not Approved" letter to the company. The decision sent Merck shares sinking 10% to 37.33 in afternoon trading Apr. 29 on the New York Stock Exchange.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.